Atherosclerotic renovascular disease (ARD) is the main cause of renal artery stenosis and is usually associated with atherosclerotic changes in the coronary, cerebral, and peripheral arteries. [1] [2] [3] A hemodynamically significant ARD is the underlying cause of renovascular hypertension, which is the most common "secondary" hypertension, as it accounts for about 5% of all hypertensives. 4 But ARD is also significantly associated with coronary artery disease (CAD) that is often clinically silent, 5 as well as with chronic or congestive heart failure and recurrent "flash" pulmonary edema. 6 Moreover, its prevalence is reported to be as high as 41% in patients reaching end-stage renal disease (ESRD). 7 The optimal management of ARD, i.e., medical therapy alone vs. renal revascularization, remains controversial. In three controlled randomized trials, there was no superiority of percutaneous renal angioplasty, [8] [9] [10] except in the subset of patients with bilateral stenoses. The end points of these studies were changes in blood pressure (BP) control or renal function.
Only observational studies have used ESRD or mortality as endpoints and these have not found differences between the two treatment modalities. 11, 12 Standard medical therapy for ARD, and in general for patients at high cardiovascular risk, consists of angiotensin inhibiting agents (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers), platelet antiaggregant agents, and lipid lowering agents-mainly statins. Benefit of angiotensin-converting enzyme inhibitor in ARD has been reported in the past, 12 but, to our knowledge, there are no studies evaluating the influence of statins on renal survival or overall mortality in these patients. Although statins have been reported to confer benefits beyond the lowering of lipids, these "pleiotropic" actions are not universally accepted. Accordingly, recommendations for use of statins in atherosclerotic patients continue to be based on lipid profile.
The current report is a retrospective observational study of 104 patients with angiographically confirmed significant ARD, comparing renal survival and overall mortality between those who did or did not receive statin therapy.
Methods
A total of 110 consecutive patients with angiographically confirmed ARD causing at least a 60% reduction in renal artery diameter, which corresponds to an 80% stenosis of the lumen of one or both main arteries, were originally included in this Background Atherosclerotic renovascular disease (ARD) coexists with arterial obstructive disease in the coronary, cerebral, and peripheral arteries that may remain underdiagnosed and untreated.
Methods this retrospective study compares overall survival and renal survival (i.e., time to doubling of serum creatinine or end-stage renal disease (ESRD)) over an 11-year period in 104 ARD patients of whom 68 received statin therapy (group S) because of elevated lipid levels and 36 had no statin (group NS) because of normal lipid profile at entry.
results

Atherosclerosis in another vascular bed was documented in 84%.
Lipid profiles at end point were virtually identical in both the groups. Group S had mean survival 123 months (confidence interval (cI) 113-134) with four deaths, and mean renal survival 122 months (cI 113-131). Group NS had mean survival 33 months (cI 23-42) with 13 deaths, and mean renal survival 27 months (cI 17-37).
conclusions Statin therapy was associated with lesser rate of progression of renal insufficiency (with 7.4% of S patients reaching renal end points vs. 38.9% of NS patients) and lower overall mortality (5.9 % in S vs. 36.1% in NS patients), P < 0.001 for both. Although both groups received what was deemed optimal therapy, they did have other differences that may have affected the outcomes (a limitation addressed by cox multiple regression analysis). these results suggest the need for prospective randomized controlled studies in ARD patients in order to explore potential benefits of statins that may not be attributable solely to lipid lowering. The local ethics committee approved the study and granted a waiver for informed consent, as this was only a retrospective survey of charts. Over the 11-year period of follow-up, patients were routinely followed by their nephrologists at the hospital's clinics at 3-4-month intervals and were hospitalized whenever deemed necessary. Prescriptions for antihypertensive agents or statins were based on the patient's BP and lipid profile, as recommended by guidelines. Recommendation for revascularization was made at the discretion of the treating physician.
Clinical and biochemical characteristics, use of other medicines, and therapeutic interventions were recorded and compared between two groups: those who received statin therapy (group S) and those who did not receive statin therapy (group NS). Glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease formula. 13 Normally distributed variables were described as mean and standard deviation and the frequencies as percentage.
Variables not normally distributed were described as median and interquartile interval. The clinical characteristics evaluated in the beginning and in the end of follow-up within groups were compared by paired t-test; the comparisons between group S and group NS were done by t-test for unpaired samples, χ² or Mann-Whitney, as appropriate. Variables with a >10% difference between the two groups were selected for multivariate (backward-stepwise) Cox proportional risk regression analysis. The elimination criterion for variables in backward stepwise analysis was P < 0.10. Categorical variables were coded as presence (1) or absence (0) to be included in the Cox model. Potential collinearity among variables selected for multiple analysis were tested and if associations were present one of the variables was excluded from the Cox model. Results were considered significant at P < 0.05.
Primary end point was death by any cause. Secondary end point was increase in serum creatinine level to double from baseline or ESRD with initiation of dialysis. Renal survival refers to progression of renal end points. Patients lost to follow-up before reaching renal end point, had no data on change in renal endpoint by 31 August 2007 or were dead before reaching the renal end point were censored for renal survival. The risk of reaching the renal or mortality end points was analyzed using the proportional risk Cox model, and was considered significant at P < 0.05. Actuarial survival curves were constructed according to the Kaplan-Meier method and compared by log-rank test.
results
The baseline clinical characteristics of the 104 patients, who are the subjects of this study, are shown in Table 1 . They were divided into two groups according to the use of statins (group S, n = 68) or nonuse of statins (group NS, n = 36). Table 2 shows their BP and biochemical characteristics at admission and at end point, as well as the final outcomes in each group. Patients in the S group had a significantly better renal function at entry (with an average GFR 39 vs. 23 in the NS group) and had significantly higher rates of use of antihypertensive and antiplatelet agents, as well as tendency to lower BP at endpoint.
Characteristics marked by "a" in these two Tables were selected for Cox multiple analysis. Decrease in BP and use of platelet antiaggregant were excluded because of collinearity with other variables. Only the use of statins maintained independent association with better patient survival ( Table 3) , whereas the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and the GFR remained at a borderline level of significance. After backward-stepwise elimination, statins and GFR are the two variables presented as the last step that remain independently associated with better patient survival, although only statins significantly reduce the relative risk of death. Table 4 shows the full model of multivariate Cox analysis of renal survival, where baseline GFR and use of statins were independently associated with renal survival. After backward-stepwise elimination of variables, these two remained as independent factors of better renal prognosis, whereas the hazard ratio of proteinuria remained borderline significant. Patient survival and renal survival curves were constructed comparing the two groups (S and NS). With a mean followup of 27 months, four deaths occurred in group S, where mean survival was 123 months, (confidence interval (CI) 113-134). In group NS mean follow-up was 15 months, there were 13 deaths and mean survival was 33 months (CI 23-42) as shown in Table 2 . Accordingly, the group of patients who used statins had better prognosis (P < 0.0001), as illustrated in Figure 1 .
Regarding the renal survival curves, group S had better prognosis than group NS, P < 0.0001 as depicted in Figure 2 . Group NS had 14 events, with mean renal survival of 27 months (CI 17-37). Group S had five events, with mean renal survival of 122 months, (CI 113-171), as shown in Table 2 .
In a further attempt to dissect the influence of baseline GFR and statin use on survival, patients in both S and NS groups were subdivided according to GFR 10-29 and 30-100 ml/min. Mean patient survival was 86 (71-102) months in S group patients with low GFR (average 18 ± 6 ml/min) vs. 22 (14-29) months (P = 0.037) in the NS group, with similar GFR (average 20 ± 5.5 ml/min). Renal survival in these two subgroups was 63 (47-78) months in S vs. 11 (5-18) months in NS, respectively, (P = 0.016). In the higher GFR subgroups, articles Statins in Atherosclerotic Renovascular Disease mean patient survival was 129 (120-139) months in the S subgroup with average GFR 52 ± 16 ml/min, vs. 44 (25-62) months (P < 0.001) in the NS subgroup, with average GFR 58 ± 20 ml/min. Mean renal survival in these two subgroups was 129 (122-137) months in S vs. 32 (16-47) months in NS patients, respectively (P < 0.001).
Causes of death in group S were myocardial infarction in two cases, bacterial peritonitis and septic shock in one case, and mesenteric ischemia in one case. In group NS there were 13 deaths: six cardiovascular deaths (four cases of stroke and two sudden deaths), three undetermined, three related to infection (peritonitis, mediastinitis, and septic shock), and one death related to malignancy.
discussion
Atherosclerosis is a systemic vascular disorder causing progressive arterial obstruction in several organs. It is usually brought to medical attention by symptoms arising from diminished perfusion of one vascular region, whereas other affected regions may remain asymptomatic for various periods of time while the disease follows a progressive course. In this article we report the results of a retrospective survey comprising 104 patients who presented with confirmed atherosclerotic stenosis of one or both renal arteries. In 84% of them there was atherosclerosis in another vascular bed (coronary, cerebral or peripheral). They were treated with what was considered optimal medical therapy (in addition to renal revascularization when appropriate), and were followed up for an average of 24 months. Sixty-eight patients had statin therapy as part of their medical regimen, whereas 36 patients had no lipid-lowering therapy. We found that the former group had a significantly lesser rate of progression of renal insufficiency (7.4% of them doubled their serum creatinine levels or reached ESRD vs. 38.9% in the latter group), and they had lower overall mortality rates, 5.9% vs. 36.1%, respectively.
Even though the percentages of pre-existing diabetes mellitus, stroke, and peripheral vascular disease and the BP levels at entry were similar in NS and S patients, a number of other differences did exist between the two groups, and these differences would obviously have affected both renal survival and overall mortality: most importantly, the NS group had a significantly more advanced renal insufficiency at entry (a lower GFR, higher serum creatinine levels, and more proteinuria). However, even when patients were divided into subgroups with similar GFR at baseline, the use of statins remained a persistent predictor of outcome. Other differences include the fact that their end point BP tended to be higher, probably because of significantly lesser use of antihypertensive agents in general and renin-suppressing drugs (angiotensinconverting enzyme inhibitors or ABRs) in particular; and they had a significantly lower rate of use of antiplatelet agents and folic acid-most likely because fewer of them had documented CAD and lower rates of coronary revascularization. On one hand, this would suggest that patients in the S group may have had a more severe and widespread atherosclerosis and were therefore considered to be at higher risk of cardiovascular mortality, which would explain their more aggressive pharmacotherapy. On the other hand, patients with more advanced chronic renal failure are more likely to have CAD which may be silent and thus might remain undiagnosed. These limitations were addressed by Cox multiple regression analysis.
It should be noted that during the period of observation, statins were prescribed only on the basis of the lipid profile, i.e., when abnormal lipid levels at entry suggested increased cardiovascular risk. However, at end point the lipid profiles of the two groups were virtually identical. Therefore, our multiple analyses of data suggested that the beneficial effect of statins in these patients with ARD were not necessarily related to the lipid levels. That statins can prevent myocardial microvascular remodeling 14 or reduce the rate of progression of renal artery stenosis has been reported also by others, 15 just as they have been found to benefit patients with atherosclerotic carotid disease 16 and CAD 17 . Because patients with ARD have widespread atherosclerotic arterial obstructions, 1-3 including silent CAD, 5 it should not be surprising that they benefit from use of statins. The fact, however, that this benefit was not attributable only to lowering of lipid levels (which were similar at end point in users and nonusers of statins) is intriguing. It could be related to the reported anti-inflammatory effects of statins 18, 19 including reduced mononuclear cell activity 16 and stabilization of atheromatous plaque, 15 as well as prevention of atheroembolic syndrome, 20 antifibrotic effect, 21 antioxidant properties, 22 or other possible pleiotropic effects not directly linked to lipid lowering. A recent meta-analysis identified 27 randomized controlled trials, in which the use of statins had beneficial effect on proteinuria and overall renal function in patients with chronic kidney disease of different etiologies. 23 In this study, proteinuria was only marginally associated with renal outcome, but other reports in the literature suggest that ARD is often associated with proteinuria, 24 which is a marker of poor prognosis. 25 Limitations of our study should be acknowledged. It is a retrospective observational study, in which the groups were not similar in terms of clinical and laboratory characteristics as discussed above, which could affect prognosis. The number of patients in this cohort was small but the very fact that it was sufficient to detect statistical differences between groups attributable to the use of statins makes the results more important. It is likely that differences would become more significant with larger numbers. These results suggest the need for controlled randomized interventional studies to confirm the potential benefit of statins that may not be necessarily attributable only to lipid lowering in patients with ARD. Currently, the use of statins in patients with atherosclerotic disease is based solely on the lipid profile, as the pleiotropic effects of statins are not universally accepted.
In fact, there are at least three ongoing prospective, randomized, controlled trials related to this topic. The Angioplasty and Stent for Renal Artery Lesion trial, 26 comparing revascularization versus medical therapy alone in ARD patients, with renal function as endpoint; the STARstudy 27 comparing renal artery stent placement along with BP and lipid-lowering and antiplatelet medications versus medications alone; and the Cardiovascular Outcomes in Renal Atherosclerotic Lesions 28 study comparing stenting plus optimal medical therapy versus optimal therapy alone, with cardiovascular as well as renal endpoints. The results of these trials may alter our perception of what is the best treatment of ARD patients for both renal preservation and overall survival.
Notably, it was also recently proposed that statin therapy should be considered for all people with diabetes, irrespective of lipid profile, 29 as these patients are also at increased risk of atherothrombotic events.
In conclusion, to the best of our knowledge, this is the first study that associated statin use in ARD with better renal and patient survival, not directly attributable to the effects on lipids. The possible mechanisms involved in this benefit are stabilization of atheromatous plaques, protection against atheroembolism, anti-inflammatory, antioxidant and antifibrotic effect.
